Sen. Herb Kohl (D-WI) has asked commissioner Andrew von
Eschenbach for info relating to the FDA's role in a decision by Genentech to
limit availability of its cancer drug Avastin to certain drug compounding
pharmacies. Kohl said some physicians have charged that Genentech is taking the
step to boost sales of its Lucentis, which is much more expensive than Avastin.